Invesque Shares Rise on Buyout by Major Shareholder Magnetar
Dow Jones2026/10/01 16:17By Adriano Marchese
Shares in real estate investment firm Invesque rose after it agreed to be taken private by its controlling shareholder Magnetar Financial, in a transaction valuing the healthcare real estate firm's publicly traded equity at about $84.1 million.
Shares rose 37% to 13 Canadian cents a share (9 cents).
Under the terms of the arrangement, a special purpose entity managed by asset management firm Magnetar will acquire all of the issued and outstanding common shares in Invesque at 10.1 U.S. cents a share.
The consideration price represents a 68% premium on a spot basis, the company said, and a 30% premium to the volume-weighted average trading price of the shares for the last 20 days ended Sept. 29.
Shares in the company have been under pressure in 2026, falling about 37% since the start of the year to 10 Canadian cents. The shares are down from a 52-week high of C$0.17.
Magnetar owns about 88% of the shares of the company, according to FactSet.
The move follows the launch of a special committee by Invesque to evaluate a potential go-private deal with Magnetar after years of asset sales and debt reductions. The Toronto-listed firm said the buyout offers minority holders an immediate liquidity exit given thin public trading volumes.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 01, 2026 12:17 ET (16:17 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Indonesian Rupiah: Limited relief, challenging backdrop – OCBC
Buying Wind in the Cryptocurrency Market! Significant Activity in Bitcoin, Ethereum, and Solana! Here are the Details…
Hulamin says Paul Baloyi resigns as independent non-executive director
Hulamin said independent non-executive director Paul Baloyi resigned, effective Oct. 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hulamin Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S604350), on October 05, 2026, and is solely responsible for the information contained therein.
US Stock Move | Pneumococcal vaccine achieves late-stage clinical trial target, Vaxcyte (PCVX.US) opens more than 50% higher
On Monday, Vaxcyte (PCVX.US) soared more than 50% at the open and was up approximately 53% at the time of writing, with a market capitalization of 12.8 billions USD.
Crypto prices
More
